Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Mitchell

Showing results (261-270 of 289) with videos related to

Pageof 29
Sort By:
Oncogene|October 5, 2021
RNA binding protein RBMS3 is a common EMT effector that modulates triple-negative breast cancer progression via stabilizing PRRX1 mRNAC James Block, Allison V Mitchell, Ling Wu, et al.
Scientific Reports|January 20, 2019
Disulfiram and BKM120 in Combination with Chemotherapy Impede Tumor Progression and Delay Tumor Recurrence in Tumor Initiating Cell-Rich TNBCLing Wu, Fanyan Meng, Lun Dong, et al.
Neuroimage. Clinical|February 15, 2021
Emotion regulation in emerging adults with major depressive disorder and frequent cannabis useEmily S Nichols, Jacob Penner, Kristen A Ford, et al.
Journal - Association of Official Analytical Chemists|January 1, 1984
Protein efficiency ratio: AACC/ASTM collaborative studyL R Hackler, C E Bodwell, M L Happich, et al.
Journal - Association of Official Analytical Chemists|March 1, 1984
Net protein ratio data: AACC-ASTM collaborative studyM L Happich, C E Bodwell, L R Hackler, et al.
Biorxiv : the Preprint Server for Biology|June 26, 2025
A whole genomic CRISPR-Cas9 screen identifies the amino acid transporter <i>SLC43A1</i> (LAT3) as a major determinant of oxaliplatin sensitivity in colorectal cancer cellsN R Pawar, H M Wade, Z Jackson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 1998
Low-dose versus standard-dose lenograstim prophylaxis after chemotherapy: a randomized, crossover comparisonG C Toner, J D Shapiro, C R Laidlaw, et al.
The American Journal of Psychiatry|February 19, 2008
Reduced amygdala response to fearful expressions in children and adolescents with callous-unemotional traits and disruptive behavior disordersAbigail A Marsh, Elizabeth C Finger, Derek G V Mitchell, et al.
Molecular Cancer Therapeutics|June 2, 2026
A whole genomic CRISPR-Cas9 screen identifies the amino acid transporter SLC43A1 (LAT3) as a major determinant of oxaliplatin sensitivity in colorectal cancer cellsNisha R Pawar, Heidi M Wade, Zoe Jackson, et al.
JCI Insight|February 10, 2026
CD9 regulates macrophage-mediated remodeling of adipose tissue in obesityJulia Chini, Nicole DeMarco, Dana V Mitchell, et al.
Pageof 29

Showing results (261-270 of 289) with videos related to

Sort By:
Pageof 29
Oncogene|October 5, 2021
RNA binding protein RBMS3 is a common EMT effector that modulates triple-negative breast cancer progression via stabilizing PRRX1 mRNAC James Block, Allison V Mitchell, Ling Wu, et al.
Scientific Reports|January 20, 2019
Disulfiram and BKM120 in Combination with Chemotherapy Impede Tumor Progression and Delay Tumor Recurrence in Tumor Initiating Cell-Rich TNBCLing Wu, Fanyan Meng, Lun Dong, et al.
Neuroimage. Clinical|February 15, 2021
Emotion regulation in emerging adults with major depressive disorder and frequent cannabis useEmily S Nichols, Jacob Penner, Kristen A Ford, et al.
Journal - Association of Official Analytical Chemists|January 1, 1984
Protein efficiency ratio: AACC/ASTM collaborative studyL R Hackler, C E Bodwell, M L Happich, et al.
Journal - Association of Official Analytical Chemists|March 1, 1984
Net protein ratio data: AACC-ASTM collaborative studyM L Happich, C E Bodwell, L R Hackler, et al.
Biorxiv : the Preprint Server for Biology|June 26, 2025
A whole genomic CRISPR-Cas9 screen identifies the amino acid transporter <i>SLC43A1</i> (LAT3) as a major determinant of oxaliplatin sensitivity in colorectal cancer cellsN R Pawar, H M Wade, Z Jackson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 1998
Low-dose versus standard-dose lenograstim prophylaxis after chemotherapy: a randomized, crossover comparisonG C Toner, J D Shapiro, C R Laidlaw, et al.
The American Journal of Psychiatry|February 19, 2008
Reduced amygdala response to fearful expressions in children and adolescents with callous-unemotional traits and disruptive behavior disordersAbigail A Marsh, Elizabeth C Finger, Derek G V Mitchell, et al.
Molecular Cancer Therapeutics|June 2, 2026
A whole genomic CRISPR-Cas9 screen identifies the amino acid transporter SLC43A1 (LAT3) as a major determinant of oxaliplatin sensitivity in colorectal cancer cellsNisha R Pawar, Heidi M Wade, Zoe Jackson, et al.
JCI Insight|February 10, 2026
CD9 regulates macrophage-mediated remodeling of adipose tissue in obesityJulia Chini, Nicole DeMarco, Dana V Mitchell, et al.
Pageof 29